EUVIMEDEUVIMED entdecken
Crossref

Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?

Shintaro Yanazume, Yukari Kirita, Yusuke Kobayashi, Ikumi Kitazono, Toshiaki Akahane, Mika Mizuno, Shinichi Togami, Akihide Tanimoto, Hiroaki Kobayashi

Acta Cytologica · 2024

DOI: 10.1159/000538288 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Cytologica, 2024. Verfasst von Shintaro Yanazume und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, s-yana@m3.kufm.kagosh…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Mutation, Immunotherapy, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Patients with polymerase epsilon (POLE) mutation (POLEmut) subtype, MMR-deficient (MMR-d) subtype as classified by The Cancer Genome Atlas (TCGA), and a high tumor mutation burden (TMB-high) potentially benefit from immunotherapy. However, characteristics of the cytological morphology within these populations remain unknown.

Methods

DNA extracted from formalin-fixed paraffin-embedded tissues was subjected to next-generation sequencing analysis. Genomic mutations related to gynecological cancers, TMB, and microsatellite instability were analyzed and were placed in four TCGA classification types. The following morphological cytological investigations were conducted on endometrial cancer using a liquid-based preparation method, prior to the commencement of initial treatment: (i) cytological backgrounds; (ii) differences between each count of neutrophils and lymphocytes as described below.

Results

Insignificant differences in the cytological background patterns of TCGA groups and TMB status were found. Although there was no significant difference in neutrophil count (p = 0.955) in the TCGA groups, POLEmut and MMR-d had significantly higher lymphocyte counts than no specific molecular profile (NSMP) (p = 0.019 and 0.037, respectively); furthermore, p53mut also tended to be significant (p = 0.064). Lymphocyte counts in TMB-high were also significantly greater than TMB-low (p = 0.002). POLEmut showed a positive correlation between TMB levels and lymphocyte counts. For predicting patients with POLEmut plus MMR-d, lymphocyte counts demonstrated a superior diagnostic accuracy of area under the curve (AUC) (0.70, 95% CI: 0.57–0.84), with a cutoff value of 26 high-power field.

Conclusion

Lymphocyte count using liquid-based cytology for patients with endometrial cancer may predict POLEmut plus MMR-d of TCGA groups and TMB-high in those who can benefit from immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsMutationImmunotherapyBiomarkers, TumorEndometriumDNA Polymerase IIHumansFemaleMiddle AgedAgedPoly-ADP-Ribose Binding ProteinsNeutrophilsAdultLymphocyte CountMicrosatellite InstabilityPredictive Value of TestsAged, 80 and overPatient SelectionDNA Mutational AnalysisLymphocytesClinical Decision-MakingCytodiagnosis

Stichwörter der Autor:innen

Endometrial cancerImmunotherapyLiquid-based cytologyLymphocytesPOLE mutation

Substanzen

Biomarkers, TumorDNA Polymerase IIPoly-ADP-Ribose Binding ProteinsPOLE protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, s-yana@m3.kufm.kagoshima-u.ac.jp.
  • Department of Pathology, Kagoshima University Hospital, Kagoshima, Japan.
  • Course of Advanced Cancer Medicine for Gynecologic Cancer, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
  • Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
  • Center for Human Genome and Gene Analysis, Kagoshima University Hospital, Kagoshima, Japan.
  • Department of Obstetrics and Gynecology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

Zitieren

APA

Yanazume, S., Kirita, Y., Kobayashi, Y., Kitazono, I., Akahane, T., Mizuno, M., Togami, S., Tanimoto, A., & Kobayashi, H. (2024). Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?. Acta Cytologica. https://doi.org/10.1159/000538288

Vancouver

Yanazume S, Kirita Y, Kobayashi Y, Kitazono I, Akahane T, Mizuno M, et al. Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?. Acta Cytologica. 2024. doi:10.1159/000538288

BibTeX
@article{Yanazume2024,
  author = {Yanazume, Shintaro and Kirita, Yukari and Kobayashi, Yusuke and Kitazono, Ikumi and Akahane, Toshiaki and Mizuno, Mika and Togami, Shinichi and Tanimoto, Akihide and Kobayashi, Hiroaki},
  title = {Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?},
  journal = {Acta Cytologica},
  year = {2024},
  doi = {10.1159/000538288}
}
Kostenlos starten →